Skip to content
Home/Companies/Pharma Services/Deallus

Deallus

Pharma Services·UK·Exited 2024·Held 9yr
Entry
2015
Hold
9yr
Exit
2024

Who owns Deallus?

Deallus was owned by ARCHIMED through MED I (2014 vintage) from 2015 to 2024, exited via Trade Sale.

Buyer identity available on Pro.

Hand-verified · updated 2026-04-21

ARCHIMED
Investor
ARCHIMED
MED I · 2014 · Buyout

Key facts

HQUnited Kingdom
SectorPharma Services
Exit Type
Trade Sale
Buyer
MOIC
–
Exit Year
2024

More from MED I

Other portfolio companies in the same fund.

Stago
Stago
Active
MedTechFrance· 2026
Fytexia
Exited 2023
HealthTechFrance· 2016
to
Micromed
Micromed
Exited 2023
MedTechFrance· 2016
to
Natural Origins
Natural Origins
Exited 2017
HealthTechFrance· 2016
to
Polyplus
Polyplus
Exited 2023
BiotechFrance· 2016
to
Primo Group
Primo Group
Exited 2024
HealthTechItaly· 2015
to

More PE-backed in Pharma

Comparable pharma deals from other GPs.

Advantice Health
Advantice Health
Active
TA AssociatesUS
Alvogen
Alvogen
Active
CVC Capital Partners
CANbridge
CANbridge
Active
General AtlanticChina
Ceva
Ceva
Exited 2025
iXO Private EquityFrance
to
curia
curia
Active
The Carlyle GroupUS
Ideal Cures Pvt. Ltd.
Ideal Cures Pvt. Ltd.
Active
TA AssociatesIndia
Track Deallus

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy Deallus?

2 strategic and 118financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on Deallus.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue